Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terazosin in Pre-Motor and Symptomatic Parkinson's Disease
NCT04386317Phase 2Active, not recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Nov 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of terazosin in Parkinson's disease (PD) and REM sleep behavior disorder (RBD), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Differences in 123I-MIBG reuptake at 26 weeks. Started Nov 2020; status: active, not recruiting.
02
Drugs
terazosin
03
Conditions
Parkinson's disease (PD)REM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on NCT04386317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04386317.